Dextrometorphan-quinidine for the treatment of pseudobulbar affect
González L, García Martí S, Pichon-Riviere A, Augustovski F, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32016001112
Spanish
Authors' recommendations:
Evidence of moderate quality shows that short-term use of dextrometorphan/quinidine would reduce the severity and number of weekly uncontrollable outbursts of laughing/crying in patients with pseudobulbar affect and diagnosed amyotrophic lateral sclerosis or multiple sclerosis when compared to placebo.
Low-quality evidence suggests that its use would also benefit patients with pseudobulbar affect secondary to dementia, traumatic brain injury and stroke.
The clinical practice guidelines that mention it, recommend it as a treatment option; it is covered by some United States health sponsors.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Humans
- Dextromethorphan
- Pseudobulbar Palsy
- Quinidine
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.